ABGSC acted as financial advisor to NattoPharma ASA (“NattoPharma” or the “Company”) in the recommended voluntary offer for all outstanding shares in NattoPharma by Compagnie des Levures Lesaffre’s (“Lesaffre”).

On 29 March 2021, Lesaffre announced that it had successfully completed the voluntary offer to acquire all the shares in NattoPharma at a price of NOK 35 per share. The offer values the total share capital of NattoPharma at approximately NOK 736 million on a fully diluted basis (excluding treasury shares). The offer price of NOK 35 per share represents a 65%, 82% and 88% premium to the volume-weighted average closing price (“VWAP”) of the Company for the one-month, three-month and six-month period prior the unaffected share price on 12 February 2021 respectively1 . The offer price further represents a 133% premium to the closing price on 2 June 2020, being the date when the Board of Directors of NattoPharma initiated its strategic review and ABG Sundal Collier was announced as financial advisor to the Company. The Board of Directors of NattoPharma unanimously recommended the shareholders of the Company to accept the offer by Lesaffre. Including option shares that Lesaffre has agreed to acquire subject to completion of the offer, Lesaffre has acquired 16,081,447 shares in the Company as of 29 March, representing in total 76.44% of the issued and outstanding shares in NattoPharma (on a fully diluted basis, excluding treasury shares). Lesaffre further intends to initiate a mandatory offer for the remaining outstanding shares of NattoPharma in accordance with applicable laws.